Rierink
Member
Two new briefings are up in Rierink's "Research briefings" section. Each summarises chemical identity, catalogue context and what the published literature reports. No protocols.
- Dulaglutide: GLP-1 Receptor Agonist in Metabolic Care: https://rierink.com/en/blog/dulaglutide-glp-1-receptor-agonist-in-metabolic-care
- Survodutide Dual Agonist: Preclinical and Clinical Evidence: https://rierink.com/en/blog/survodutide-dual-agonist-preclinical-and-clinical-evidence
All briefings: https://rierink.com/en/blog
Janoshik Testing Fund (vote on what gets tested next): https://rierink.com/en/blog/janoshik-testing-fund
Rierink, Porto, Portugal.
For laboratory research use only. Not for human or veterinary use.
- Dulaglutide: GLP-1 Receptor Agonist in Metabolic Care: https://rierink.com/en/blog/dulaglutide-glp-1-receptor-agonist-in-metabolic-care
- Survodutide Dual Agonist: Preclinical and Clinical Evidence: https://rierink.com/en/blog/survodutide-dual-agonist-preclinical-and-clinical-evidence
All briefings: https://rierink.com/en/blog
Janoshik Testing Fund (vote on what gets tested next): https://rierink.com/en/blog/janoshik-testing-fund
Rierink, Porto, Portugal.
For laboratory research use only. Not for human or veterinary use.